{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T19:41:10Z","timestamp":1780602070301,"version":"3.54.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014941","name":"Cytokinetics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014941","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s40256-024-00674-0","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T14:49:16Z","timestamp":1724424556000},"page":"801-811","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Differences in Healthcare Resource Use and Cost by Pharmacotherapy Among Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: Real-World Analysis of Claims Data"],"prefix":"10.1007","volume":"24","author":[{"given":"Michael","family":"Butzner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eros","family":"Papademetriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Potluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanatan","family":"Shreay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,22]]},"reference":[{"issue":"39","key":"674_CR1","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","volume":"35","author":"PM Elliott","year":"2014","unstructured":"Elliott PM, Anastasakis A, Authors\/Task Force members, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733\u201379. https:\/\/doi.org\/10.1093\/eurheartj\/ehu284.","journal-title":"Eur Heart J"},{"key":"674_CR2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.amjcard.2021.08.024","volume":"159","author":"M Butzner","year":"2021","unstructured":"Butzner M, Maron M, Sarocco P, et al. Clinical diagnosis of hypertrophic cardiomyopathy over time in the United States (A Population-Based Claims Analysis). Am J Cardiol. 2021;159:107\u201312. https:\/\/doi.org\/10.1016\/j.amjcard.2021.08.024.","journal-title":"Am J Cardiol"},{"issue":"5","key":"674_CR3","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.006657","volume":"7","author":"DY Lu","year":"2018","unstructured":"Lu DY, Pozios I, Haileselassie B, et al. Clinical outcomes in patients with nonobstructive, labile, and obstructive hypertrophic cardiomyopathy. J Am Heart Assoc. 2018;7(5): e006657. https:\/\/doi.org\/10.1161\/JAHA.117.006657.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"674_CR4","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1080\/13696998.2021.1978242","volume":"24","author":"SS Jain","year":"2021","unstructured":"Jain SS, Li SS, Xie J, et al. Clinical and economic burden of obstructive hypertrophic cardiomyopathy in the United States. J Med Econ. 2021;24(1):1115\u201323. https:\/\/doi.org\/10.1080\/13696998.2021.1978242.","journal-title":"J Med Econ"},{"issue":"25","key":"674_CR5","doi-asserted-by":"publisher","first-page":"e558","DOI":"10.1161\/CIR.0000000000000937","volume":"142","author":"SR Ommen","year":"2020","unstructured":"Ommen SR, Mital S, Burke MA, et al. 2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines [published correction appears in Circulation. 2020 Dec 22;142(25):e633]. Circulation. 2020;142(25):e558\u2013631. https:\/\/doi.org\/10.1161\/CIR.0000000000000937.","journal-title":"Circulation"},{"issue":"5","key":"674_CR6","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.amjcard.2012.04.051","volume":"110","author":"S Nistri","year":"2012","unstructured":"Nistri S, Olivotto I, Maron MS, et al. \u03b2 Blockers for prevention of exercise-induced left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2012;110(5):715\u20139. https:\/\/doi.org\/10.1016\/j.amjcard.2012.04.051.","journal-title":"Am J Cardiol"},{"key":"674_CR7","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.amjcard.2022.03.023","volume":"174","author":"M Butzner","year":"2022","unstructured":"Butzner M, Sarocco P, Maron MS, et al. Characteristics of patients with obstructive hypertrophic cardiomyopathy in real-world community-based cardiovascular practices. Am J Cardiol. 2022;174:120\u20135. https:\/\/doi.org\/10.1016\/j.amjcard.2022.03.023.","journal-title":"Am J Cardiol"},{"issue":"13","key":"674_CR8","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.3390\/jcm11133898","volume":"11","author":"M Butzner","year":"2022","unstructured":"Butzner M, Rowin E, Yakubu A, et al. Clinical characteristics and healthcare resource utilization among patients with obstructive hypertrophic cardiomyopathy treated in a range of settings in the United States. J Clin Med. 2022;11(13):3898. https:\/\/doi.org\/10.3390\/jcm11133898.","journal-title":"J Clin Med"},{"issue":"10253","key":"674_CR9","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","volume":"396","author":"I Olivotto","year":"2020","unstructured":"Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial [published correction appears in Lancet. 2020 Sep 12;396(10253):758]. Lancet. 2020;396(10253):759\u201369. https:\/\/doi.org\/10.1016\/S0140-6736(20)31792-X.","journal-title":"Lancet"},{"issue":"1","key":"674_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jacc.2022.10.020","volume":"81","author":"MS Maron","year":"2023","unstructured":"Maron MS, Masri A, Choudhury L, et al. Phase 2 Study of Aficamten in Patients\u00a0With Obstructive Hypertrophic\u00a0Cardiomyopathy. J Am Coll Cardiol. 2023;81(1):34\u201345. https:\/\/doi.org\/10.1016\/j.jacc.2022.10.020.","journal-title":"J Am Coll Cardiol"},{"key":"674_CR11","unstructured":"CY 6031 Study Will Evaluate the Effects of Treatment With Aficamten (CK-3773274) Over a 24-week Period on Cardiopulmonary Exercise Capacity and Health Status in Patients With Symptomatic oHCM (SEQUOIA-HCM)"},{"key":"674_CR12","unstructured":"Cytokinetics. Cytokinetics Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy. December 27, 2023, https:\/\/ir.cytokinetics.com\/news-releases\/news-release-details\/cytokinetics-announces-positive-results-sequoia-hcm-pivotal. Accessed 18 Jan 2024"},{"key":"674_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahjo.2022.100089","volume":"13","author":"M Butzner","year":"2022","unstructured":"Butzner M, Maron MS, Sarocco P, et al. Healthcare resource utilization and cost of obstructive hypertrophic cardiomyopathy in a US population. Am Heart J ournal Plus Cardiol Res Pract. 2022;13: 100089. https:\/\/doi.org\/10.1016\/j.ahjo.2022.100089.","journal-title":"Am Heart J ournal Plus Cardiol Res Pract"},{"issue":"12","key":"674_CR14","doi-asserted-by":"publisher","first-page":"E866","DOI":"10.25270\/jic\/22.00150","volume":"34","author":"M Butzner","year":"2022","unstructured":"Butzner M, Maron MS, Sarocco P, et al. Costs and healthcare resource utilization for obstructive hypertrophic cardiomyopathy with septal reduction therapy. J Invasive Cardiol. 2022;34(12):E866\u201372.","journal-title":"J Invasive Cardiol"},{"issue":"2","key":"674_CR15","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40119-022-00257-7","volume":"11","author":"AT Owens","year":"2022","unstructured":"Owens AT, Sutton MB, Gao W, et al. Treatment changes, healthcare resource utilization, and costs among patients with symptomatic obstructive hypertrophic cardiomyopathy: a claims database study. Cardiol Ther. 2022;11(2):249\u201367. https:\/\/doi.org\/10.1007\/s40119-022-00257-7.","journal-title":"Cardiol Ther."},{"issue":"1","key":"674_CR16","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1080\/13696998.2023.2208966","volume":"26","author":"SS Naidu","year":"2023","unstructured":"Naidu SS, Sutton MB, Gao W, et al. Frequency and clinicoeconomic impact of delays to definitive diagnosis of obstructive hypertrophic cardiomyopathy in the United States. J Med Econ. 2023;26(1):682\u201390. https:\/\/doi.org\/10.1080\/13696998.2023.2208966.","journal-title":"J Med Econ"},{"key":"674_CR17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.amjcard.2022.12.030","volume":"192","author":"NR Desai","year":"2023","unstructured":"Desai NR, Sutton MB, Xie J, et al. Clinical outcomes, resource utilization, and treatment over the disease course of symptomatic obstructive hypertrophic cardiomyopathy in the United States. Am J Cardiol. 2023;192:16\u201323. https:\/\/doi.org\/10.1016\/j.amjcard.2022.12.030.","journal-title":"Am J Cardiol"},{"issue":"17","key":"674_CR18","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1161\/CIRCULATIONAHA.119.044366","volume":"141","author":"P Marstrand","year":"2020","unstructured":"Marstrand P, Han L, Day SM, et al. Hypertrophic cardiomyopathy with left ventricular systolic dysfunction: insights from the SHaRe Registry. Circulation. 2020;141(17):1371\u201383. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.044366.","journal-title":"Circulation"},{"key":"674_CR19","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/S0735-1097(21)01893-3","volume":"77","author":"Hoss","year":"2021","unstructured":"Hoss, et al. JACC. 2021;77:534.","journal-title":"JACC"},{"issue":"10","key":"674_CR20","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.3390\/jcm9103062","volume":"9","author":"I Byty\u00e7i","year":"2020","unstructured":"Byty\u00e7i I, Nistri S, M\u00f6rner S, Henein MY. Alcohol septal ablation versus septal myectomy treatment of obstructive hypertrophic cardiomyopathy: a systematic review and meta-analysis. J Clin Med. 2020;9(10):3062. https:\/\/doi.org\/10.3390\/jcm9103062.","journal-title":"J Clin Med"},{"issue":"1","key":"674_CR21","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.cardfail.2023.10.201","volume":"30","author":"AM Altibi","year":"2024","unstructured":"Altibi AM, Elman M, Zhao Y, et al. Cardiovascular hospitalizations post septal myectomy for obstructive hypertrophic cardiomyopathy: a 3-year analysis of 5,101 patients. J Cardiac Fail. 2024;30(1):199\u2013200. https:\/\/doi.org\/10.1016\/j.cardfail.2023.10.201.","journal-title":"J Cardiac Fail"},{"issue":"13_Supplement","key":"674_CR22","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S0735-1097(24)02542-7","volume":"83","author":"T Post","year":"2024","unstructured":"Post T, Elman M, Kim M, et al. Standard of care medication patterns of use before and after septal myectomy in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2024;83(13_Supplement):552. https:\/\/doi.org\/10.1016\/S0735-1097(24)02542-7.","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"674_CR23","doi-asserted-by":"publisher","first-page":"e1239","DOI":"10.1161\/CIR.0000000000001250","volume":"149","author":"SR Ommen","year":"2024","unstructured":"Ommen SR, Ho CY, Asif IM, et al. 2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a Report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(23):e1239\u2013311. https:\/\/doi.org\/10.1161\/CIR.0000000000001250.","journal-title":"Circulation"},{"issue":"37","key":"674_CR24","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","volume":"44","author":"E Arbelo","year":"2023","unstructured":"Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023;44(37):3503\u2013626. https:\/\/doi.org\/10.1093\/eurheartj\/ehad194.","journal-title":"Eur Heart J"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-024-00674-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-024-00674-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-024-00674-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T16:30:11Z","timestamp":1730305811000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-024-00674-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,22]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["674"],"URL":"https:\/\/doi.org\/10.1007\/s40256-024-00674-0","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,22]]},"assertion":[{"value":"5 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M. Butzner and S. Shreay are full-time employees and hold stock of Cytokinetics Incorporated. E. Papademetriou, R. Potluri, and X. Liu have no disclosures to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"This author takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of Authorship"}},{"value":"M. Butzner: conceptualization, methodology, investigation, supervision, validation, visualization, project administration, writing\u2014original draft preparation, and reviewing and editing. E. Papademetriou and X. Liu: conceptualization, methodology, data curation, data analysis, validation, visualization, and writing\u2014reviewing and editing. R. Potluri: investigation, data curation, data analysis, project administration, and writing\u2014reviewing and editing. Sanatan Shreay: conceptualization, methodology, investigation, validation, and writing\u2014reviewing and editing.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"This work was funded by Cytokinetics Incorporated.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"M. Butzner and S. Shreay are full-time employees and hold stock of Cytokinetics Incorporated. E. Papademetriou, R. Potluri, and X. Liu are employees of Putnam Associates, which was contracted to perform the analyses.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All data generated or analyzed during this study are included in this published article.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}},{"value":"This study did not require approval from an institutional review board.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Not applicable.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":11,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}